Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Teijin Ltd. engages in the management of its group companies that are involved in the environment and energy, safety and protection, information and electronics, transportation, and healthcare businesses. It operates through the following segments: Materials, Healthcare, and Others. The Materials segment handles the manufacture and sale of polyester, aramid, and carbon fiber products as well as plastic and resin products from polycarbonate resin and polyester film. The Healthcare segment deals with the manufacture and sale of pharmaceuticals and home medical equipment. It also provides home healthcare services. The Others segment offers information technology services. The company was founded by Seita Kumura, Itsuzo Hata, and Naokichi Kaneko on June 17, 1918 and is headquartered in Osaka, Japan.

Arriva Pharmaceuticals, Inc., founded in 1997, is a privately held biopharmaceutical company focused on the development and commercialization of recombinant protease inhibitors for treatment of a wide range of human diseases. The areas of therapeutic focus are: - Respiratory diseases: hereditary emphysema, asthma, chronic obstructive pulmonary disorder (COPD) and cystic fibrosis. - Dermatological diseases: atopic dermatitis, psoriasis. - Inflammatory ear diseases: otitis media, otitis externa. - Oncology: breast cancer, prostate cancer. The company has developed technology for large-scale production of stable, non-animal sourced recombinant proteins in yeast. Using this technology, GMP, Good Manufacturing Practice, clinical grade recombinant alpha 1-antitrypsin (AAT) has been produced for clinical trials for respiratory and dermatological indications and maspin will be produced for treatment of breast and prostate cancer. In January, 2001 the company changed its name from AlphaOne Pharmaceuticals, Inc. to Arriva Pharmaceuticals, Inc. to reflect an expansion from a single product focus to a more diversified drug product pipeline.

Janssen Pharmaceutica is a pharmaceutical company headquartered in Beerse, Belgium and owned by Johnson & Johnson. It was founded in 1953 by Paul Janssen. In 1961, Janssen Pharmaceutica was purchased by New Jersey-based American corporation Johnson & Johnson, and became part of Johnson & Johnson Pharmaceutical Research and Development (J&J PRD), now renamed to Janssen Research and Development (JRD), which conducts research and development activities related to a wide range of human medical disorders, including mental illness, neurological disorders, anaesthesia and analgesia, gastrointestinal disorders, fungal infection, HIV/AIDS, allergies and cancer. Janssen and Ortho-McNeil Pharmaceutical have been placed in the Ortho-McNeil-Janssen group within Johnson & Johnson Company.

Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ.

CuraGen Corporation is a biopharmaceutical development company that develops novel therapeutics for the treatment of cancer in the United States and Europe. Its therapeutics is based on novel targets from the human genome that play a role in proven mechanisms underlying disease. The Company's strategy continues to be focused on advancing its pipeline of pipeline of protein, antibody, and small molecule drugs in the areas of oncology, inflammatory diseases, and diabetes, promising therapeutics through clinical and preclinical development. CuraGen Corporation was founded in 1991 and is headquartered in Branford, Connecticut. As of October 1, 2009, CuraGen Corporation operates as a subsidiary of Celldex Therapeutics, Inc.

Inhibrx LP developed therapeutic antibodies and pharmaceuticals. Its programs focused on oncology, inflammatory and metabolic diseases and these programs are based on an implementation of multiple antibody and biologic development strategies for therapeutic lead generation, selection, functional enhancement, and optimization. The firm's platforms enabled fit-for-function biotherapeutics that interface with the biology of each target antigen, focus immune activation, and mediate enhanced signaling. The company was founded by Quinn Deveraux, Brendan Eckelman, and Mark Paul Lappe in 2010 and was headquartered in La Jolla, CA.

Cambridge University Technical Services Ltd., part of University of Cambridge, is a British company located in Cambridge. The firm provides consulting services. It was founded in 2006.

TriPath Imaging, Inc. manufactures and markets diagnostic equipment and products for cervical cytology screening. The company’s products include microbial identification tests for differential detection and identification of the causative agents for vaginitis; ethanol based fixative systems to collect, preserve, hemolyze, transport, and transfer cytology specimens to a glass slide; slide profilers for prioritizing slides based on likelihood of abnormality to help cytotechnologists reduce false negatives;

Arena Pharmaceuticals, Inc. is a biopharmaceutical company founded in 1997 and located in San Diego, California. The company has small molecule drugs in development for possible clinical utility in multiple therapeutic areas. The company’s most advanced investigational clinical programs are ralinepag (formerly APD811) in testing for pulmonary arterial hypertension (PAH), etrasimod (formerly APD334) in evaluation for inflammatory indications and APD371 for the treatment of pain associated with Crohn’s disease. In 2016 the company downsized and shifted its focus to developing new drugs currently being tested in clinical trials.

Distributes electricity

Robatel SA is a French private company located in Paris that operates in several countries and functions as an investment holding company.

Amgen Boulder, Inc., a subsidiary of Amgen, Inc., is a company headquartered in Longmont, CO. The firm discovers, develops, and produces protein-based human pharmaceuticals.

Massachusetts General Hospital was established to provide care to Boston's sick, regardless of socioeconomic status—an innovative idea in 1811. In the words of their founder, John Warren, MD, “When in distress, every man becomes their neighbor.” They subsequently became the first teaching hospital for Harvard University’s new medical school and have been redefining excellence in healthcare ever since. They have remained at the forefront of medicine by fostering a culture of collaboration, pushing the boundaries of medical research, educating the brightest medical minds and maintaining an unwavering commitment to the diverse community they were created to serve. They believe that because of diversity they excel, through inclusion they respect their community, and with a keen focus on equity they serve, heal, educate and innovate at the highest levels. Their first priority is the well-being of their patients—near and far. As a team they are able to maintain a singular focus on providing the highest quality, most compassionate care to each and every patient.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Randox Laboratories Ltd. provides clinical diagnostic solutions to laboratories. It develops, manufactures and markets high quality diagnostic reagents and equipment for laboratory medicine. The firm's products include Biochip Array Technology, clinical chemistry analyzers and reagents, quality control materials and schemes and an extensive life science portfolio. The company was founded by Peter FitzGerald in April 1982 and is headquartered in Crumlin, the United Kingdom.